Unusual manifestation of Erdheim-Chester disease
Antony Pan1, Terence Doyle2,3, Martin Schlup1,3, Ralf Lubcke1 and Michael Schultz1,3*

Abstract

Background: Erdheim-Chester disease (ECD) is a rare multisystem non-Langerhans cell histiocytosis that is characterized histologically by xanthogranulomatous infiltrates and radiologically by symmetrical sclerosis of long bones. The xanthomatous process is characterized by prominent foamy histiocytes staining positive for CD68, occasionally for PS100 and negative for S100 and CD1a. Gastroenterological involvement is exceedingly rare.

Case Presentation: This case report describes the case of a 69-year-old man who presented otherwise well to the gastroenterology department with unspecific abdominal symptoms, nausea, vomiting and weight loss. ECD involving the gastrointestinal tract was confirmed clinically, radiologically and histologically.

Conclusion: Gastroenterological manifestation of ECD is rare but should be considered in the differential diagnosis in patients presenting with evidence of multi-organ disease and typical radiological features of Erdheim-Chester disease elsewhere.

Background

Erdheim-Chester Disease (ECD) is a rare multisystem histiocytosis characterized by the xanthomatous or xanthogranulomatous infiltration of tissues with histiocytes, surrounded by fibrosis. The disease can affect multiple organs systems, but gastrointestinal involvement, is exceedingly rare. We describe here the case of a 69-year old man with ECD who presented to the gastroenterology department with unspecific abdominal symptoms, nausea, vomiting and weight loss.

Case presentation

A previously fit and well 69-year-old man was admitted to the gastroenterology department with a short one month history of lethargy, decreased appetite, persistent vomiting, significant weight loss of six kilograms over 1 month and a dry cough. He denied abdominal pain, haematemesis, dysphagia and a change in bowel habit and described no cardiac, respiratory, neurological symptoms or bone pain. His past medical history includes appendectomy and total hip joint replacement. At the time of admission, he was not on any regular medication.

Physical examination revealed that he was febrile (38.8°C) and appeared cachetic but with no peripheral stigmata of chronic liver disease. His abdominal examination revealed hepatomegaly but no other organomegaly, per rectal examination was unremarkable. His cardiopulmonary examinations were unremarkable apart from bilateral pitting edema up to his ankles. Peripheral blood analysis revealed an anaemia of chronic disease with hemoglobin of 108 g/L (norm - male 130 - 175 g/L), serum iron 2 μmol/L (norm 10 - 30 μmol/L), transferrin 1.4 g/L (2 - 3.5 g/L), transferrin saturation 6% (norm 16 - 50%) and ferritin 354 μg/L (norm 20 - 500 μg/L). Consistent with a systemic illness the c-reactive protein was increased to 208 mg/L (norm < 5 mg/L) but multiple urine and blood cultures were negative for bacterial infection. Normal serum electrolytes and creatinine of 83 μmol/L (norm 50 - 120 μmol/L). Liver function test was normal apart from a marked hypoalbuminaemia of 28 g/L (norm 35 - 50 g/L). Protein electrophoresis, Vitamin B12, folate, and thyroid functions were normal. Chest X-ray showed interstitial infiltration involving both lung bases. Lung function test was consistent with a restrictive lung disease (FVC 3.33 L (73%), FEV1 2.49 L (72%), FEV1/FVC 75% and decreased in diffusion capacity (DLCO 17.81 ml/min/mmHg). Ultrasound of the abdomen confirmed a 19 cm hepatomegaly, with normal liver texture and no evidence of a mass lesion.
Due to ongoing vomiting and weight loss, a gastroscopy was performed with no significant pathology. Computer tomography (CT) of the chest showed peri-aortic tissue infiltration creating the appearance of “coated aorta” (Figure 1) as well as thickening of the interlobular septa in both lungs (Figure 2). The infiltration processes also involved the pulmonary vessels, pericardium, lung parenchyma and the oesophagus. CT of the abdomen showed hypo-attenuated homogenous tissue infiltration with weak contrast enhancement in the renal fossa. Symmetric and bilateral infiltration of the peri-renal, anterior and posterior para-renal spaces gave the appearance of “hairy kidney” (Figure 3). Inferior vena cava, aorta and mesentery were also involved. These findings were seen as consistent with a possible diagnosis of Erdheim-Chester Disease (ECD) [1-3].

A CT guided biopsy of the retroperitoneal space and a bone marrow aspiration were performed which were inconclusive, consistent with reactive inflammatory processes. To confirm the diagnosis of ECD a laparotomy was performed to obtain tissue for diagnostic purposes. Operative findings revealed an infiltrating process involving the liver, omentum and small bowel mesentery. Biopsies were taken from the liver (Figure 4), the omentum (Figure 5) and mesenteric lymph nodes (Figure 6). Histological examination of the tissue showed xanthomatous infiltration involving the liver, omentum and surrounding the lymph nodes. The xanthomatous process was characterized by prominent foamy histiocytes, admixed with occasional giant cells and chronic inflammatory cells. Immunohistochemical stains revealed that these cells were positive for CD68 and negative for S100 and CD1a. There was no evidence of malignancy and the findings allowed a diagnosis of severe multi-organ ECD [1].

Subsequent magnetic resonance imaging (MRI) (Figure 7) of the whole body showed an increased marrow signal in the distal femur and proximal tibia consistent with ECD [4]. Due to further rapid decline, the patient was started on total parenteral nutrition, IV hydrocortisone at 1 g once daily for 2 days, then 500 mg once daily for 8 days before changing to oral prednisone at 100 mg (1 mg/kg/day) for a week. The prednisone dose was then tapered down to 30 mg once daily. Although the patient’s appetite improved after the initiation of steroid treatment, hypoalbuminaemia persisted and thrombocytopenia developed. One month after initiation of treatment the patient died of respiratory failure.
Conclusion

Erdheim-Chester Disease (ECD) is a rare multisystem non-Langerhans cell histiocytosis first described by Jakob Erdheim and William Chester in 1930 [5] and since then approximately 400 cases have been reported [6]. It is characterized by the xanthomatous or xanthogranulomatous infiltration of tissues with foamy histiocytes, surrounded by fibrosis. The aetiology of the disease remains unknown. The disease can affect multiple organs systems, including musculoskeletal, central nervous, cardiac, pulmonary and renal systems. Gastrointestinal involvement, despite being seen more often in other histiocytoses [7], is exceedingly rare and to our knowledge there are 2 case reports regarding involvement of the liver and biliary system [4,8].

Two criteria, of which one should be fulfilled, were proposed by Veyssier-Belot [1] in 1996 as a requirement for the diagnosis of ECD. (1) Typical histological findings with foamy histiocytes nested among polymorphic granuloma and fibrosis or xanthogranulomatosis with CD68-positive and CD1a-negative immunohistochemical staining. (2) Typical skeletal findings with a) radiographs showing bilateral and symmetric osteosclerosis of the diaphyseal and metaphyseal regions in the bones and/or b) symmetric and abnormally increased labeling of the distal ends of the long bones of the lower limbs, and sometimes the upper limbs, on 99Tc bone scintigraphies.

There are typical radiological and pathological features which can lead to the diagnosis, but the clinical spectrum shows a broad variation, ranging from asymptomatic tissue infiltration to fulminant multisystem organ failure.

Bone pain is the most common presenting symptom of ECD mainly affecting the legs, especially knees and

Figure 4 Histology of the liver showed a predominantly histiocytic (foamy histiocytes) infiltrate.

Figure 5 Biopsy of omentum showed histiocytic infiltrate.

Figure 6 Biopsy of mesenteric lymph nodes showed evidence of perinodal histiocytic infiltrate.

Figure 7 MRI scan showed an increased marrow signal in the distal femur and proximal tibia.

Pan et al. BMC Gastroenterology 2011, 11:77
http://www.biomedcentral.com/1471-230X/11/77
Page 3 of 5
ankles and has been reported in 47-86% of patients with ECD [1,9-12]. About half of all patients have extra-skeletal manifestations including retroperitoneal fibrosis, orbital infiltration, interstitial lung disease [2,13], bilateral adrenal involvement [14], testis infiltration [15], breast, central nervous [9,16,17] and/or cardiovascular system [18]. Other general symptoms such as fever, weight loss and weakness can also occur.

Retroperitoneal involvement is secondary to infiltration of the fat and surrounding structures by histiocytes and associated fibrosis. This process can lead to renal and/or ureteral obstruction causing renal impairment. This is reported to occur in 29-59% of patients with ECD [1,19]. Erdheim-Chester infiltration is distinguished from retroperitoneal fibrosis principally by its many foamy histiocytes, lack of plasma cells, and lack of vasculitis [20].

The cardiovascular manifestations of ECD have been known to exist since the disease was first described; this occurs in about 40% of the patients with peri-aortic "fibrosis" as the most frequent cardiovascular involvement. Other manifestations include heart failure, valvular dysfunction, reno-vascular hypertension and pericarditis [18]. It was previously thought that only about 20% of patients have lung involvement however, a recent study reported clinical and/or radiological pulmonary involvement in up to 59% of patients [2]. Usually patients present with dyspnea or a dry cough [2]. Most patients have mediastinal infiltration, diffuse interstitial infiltrates and pleural and/or interlobar septal thickening best seen on high-resolution CT [3]. Characteristic lung histopathology includes the accumulation of histiocytes with variable amounts of fibrosis and a variable lymphoplasmacytic infiltrate in a lymphangitic distribution [13].

The involvement of liver, pancreas, mesentery and gastrointestinal tract is extremely rare [8,4]. The diagnosis of ECD in our patient was challenging as he presented with unspecific symptoms such as a decrease in appetite, persistent vomiting, weight loss and fever. He had features of malnutrition with cachexia, peripheral oedema secondary to hypoalbuminaemia. Evidence of both hepatic and mesenteric involvement of ECD was present, with operative findings of liver, omentum and small bowel mesentery infiltration. Liver biopsy showed xanthomatous infiltration with prominent foamy histiocytes positive for CD68 and negative for S100 and CD1a. Biopsies also confirmed the involvement of mesenteric lymph nodes and the omentum. It was interesting to see that a normal liver function test does not preclude the involvement of the liver by histiocytic infiltration in ECD. Our patient also showed features consistent with skeletal involvement with MRI demonstrating increased marrow signal in the distal femur and proximal tibia. Although bone pain is the most common presenting of ECD, he remained asymptomatic from his skeletal lesions. Other features of ECD demonstrated in our patient include retroperitoneal, cardiovascular and respiratory involvement.

Various therapies for ECD have been proposed, including corticosteroids [1], multiple chemotherapeutic regimes including vinblastine, vincristine, cyclophosphamide, doxorubicin [1], cladribine [1,21-23], radiotherapy [19,24], cyclosporine and alpha interferon [1]. The latter treatment has gained some attention recently with the initial report of a durable response in three patients [25]. This was followed by a series report of treatment with interferon-alpha in eight patients with variable response. While treatment with interferon-alpha is promising, mechanisms of action are still largely unknown [26]. Prognosis of the disease depends largely on the extent and distribution of the extra-skeletal, in particular cardio-vascular [26] and central nervous system [6] involvement. Based on these results it was suggested by the authors that interferon-alpha is considered as a first-line treatment for patients with ECD but a 40% mortality in the first 40 months after diagnosis has still to be accepted [26].

In summary, we describe the case of a 69-year-old man who presented to the gastroenterological department with unspecific symptoms of fever, fatigue, decreased appetite, persistent vomiting and weight loss. He had clinical, radiological and histological features consistent with gastrointestinal involvement of ECD. He also demonstrated the involvement of skeletal, retroperitoneal, cardiovascular, and respiratory system. He fulfilled the two criteria proposed by Veyssier-Belot1 in 1996 for the diagnosis of Erdheim-Chester disease. Although a bone scan was not performed, the MRI STIR showed an increased marrow signal in the distal femur and proximal tibia. Even though bone pain is the most commonly presenting symptom in ECD, apart from general unspecific symptoms, our patient did not show any evidence of bone pain. Despite the multiple extra-skeletal manifestations seen radiologically, gastroenterological manifestation of ECD is rare but should be considered in the differential diagnosis in patients presenting with evidence of multi-organ disease and typical radiological features of Erdheim-Chester disease elsewhere.

Acknowledgements
Written consent was obtained from the patient for publication of study. Special thanks to Dr Michael Lau, Pathologist, Southern Community Laboratories, Dunedin for his provision of histology slides.

Author details
1Gastroenterology Unit, Southern District Health Board, Dunedin, New Zealand. 2Department of Radiology, Southern District Health Board, Dunedin, New Zealand. 3Department of Medicine, University of Otago, Dunedin, New Zealand.
Authors’ contributions
AP was involved in the treatment of the patient, consulted the literature and drafted the manuscript. MS and RL participated in the design of the study and analysis of the results. MS, corresponding author was supervising the study, conducted the literature review and assisted in the writing of the manuscript. All authors read and approved the manuscript.

Authors’ information
Dr Pan is an advanced trainee in gastroenterology and general medicine at the Dunedin Hospital, Southern District Health Board, New Zealand.

Competing interests
The authors declare that they have no competing interests.

Received: 21 March 2011 Accepted: 22 June 2011
Published: 22 June 2011

References
1. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, Wallaert B, Petit H, Grimaldi A, Wechsler B, Godreau P. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine 1996, 75:157-169.
2. Arnaud L, Pierre I, Beigelman-Aubry C, Capron F, Brun B, Néel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Agusti P. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010, 20:2579-87.
3. Graziani G, Amoura Z, Haroche J: Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010, 62:5904-12.
4. Arnaud L, Toutou-Gottenberg D, Haroche J, Toledano D, Cluzel P, Beigelman-Aubry C, Piette JC, Amoura Z, Grenier PA. Erdheim-Chester disease: report of two cases and review of the literature. Am J Gastroenterol 2007, 102:452-4.
5. Chester W: Über Lipoid Granulomatose. Virchows Arch Pathol Anat 1930, 279:561-602.
6. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzet TJ, Dubourgquet F, Marinho A, Magnette C, Noel V, Pavic M, Casper J, Beauch A, Costedoat-Chalumeau N, Aaron L, Salvatierra J, Graux C, Cacoub P, Isnard R, Généreau T, Bindi P, Herbaut C, Graziani G, Amoura Z, Haroche J. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011, 117:2778-82.
7. Singh AD, Montgomery EA: Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol 2011, 35:305-10.
8. Gupta A, Aman K, Al-Batnain M, Al-Wazzan H, Morouf R. Multisystem Erdheim-Chester disease: a unique presentation with liver and axial skeletal involvement. Br J Haematol 2007, 138:280.
9. Lalencat F, Cotton F, Desmurs-Clavel H, Hanao J, Taillia H, Magy N, Hamidou M, Salvatierra J, Graux C, Pette JC, Vital-Durand D, Rousset H: CNS involvement in Erdheim-Chester disease: report of 6 cases and systemic review of the literature. Int J Clin Oncol 2007, 12:238-4.
10. Franaszczuk C, Skol J, Bremer C, Kempe M, Schober O. Determination of extent and activity of radionuclide imaging in Erdheim-Chester disease. Clin Nucl Med 1999, 24:252-255.
11. Sandrock D, Berne OR, Scheffknecht B, Neumann RD. Scintigraphic findings and follow up in Erdheim-Chester disease. Eur J Nucl Med 1990, 16:55-60.
12. Dion E, Gref C, Miquel A, Haroche J, Wechsler B, Amoura Z, Zeitoun D, Grenier PA, Pette JC, Laredo JD. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006, 238:632-9.
13. Allen T, Connors R, Sherar D, Cagle PT. Pulmonary and orthopedic involvement with Erdheim-Chester disease: a case report and review of the literature. Arch Pathol Lab Med 2004, 128:428-31.
14. Haroche J, Amoura Z, Traonoue P, Sellaheen D, Gref C, Birmelé B, Wechsler B, Cluzel P, Grenier PA, Pette JC. Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 2007, 6:2007-12.
15. Sheu S, Wang Z, Kersting C, Merten R, Otterbach F, Schmidt KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes and a review of literature. J Clin Pathol 2004, 57:1225-1228.
16. Wright H, Heimann R, Parisi J: Neurological manifestations of Erdheim-Chester disease. J Neurol Neurosurg Psychiatry 1999, 66:672-75.
17. Caparros-Lefebvre D, Pravo JP, Remy M, Wallaert B, Petit H. Neuroradiological aspects of Chester-Erdheim disease. Am J Neuroradiol 1995, 16:735-740.
18. Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, Isnard R, Généreau T, Wechsler J, Weber N, Gref C, Cluzel P, Grenier P, Pette JC. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease report of 6 new cases and a literature review. Medicine (Baltimore) 2004, 83:71-92.
19. Mascali M, Nencini P, Nisti M, Sarti C, Santonisi R. Failure of radiation therapy for brain involvement in Erdheim-Chester disease. J Neurol 2002, 15:216-172.
20. Elle J, Rosenberg A, Young R. Retroperitoneal xanthogranuloma in a patient with Erdheim-Chester disease. Am J Surg Pathol 1994, 18:443-8.
21. Serratrice J, Ganel B, De Roux C, Pellissier JF, Sänder L, Bartoli JM, Doidier P, Weiller PJ. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol 2000, 27:1550-1553.
22. Sheldow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye 2000, 14(PT 4):606-612.
23. Myra C, Soper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, Sokal M, Haynes AP, Powell RJ. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004, 88:444-447.
24. Matsu K, Nagata Y, Hiraoka: Radiotherapy for Erdheim-Chester disease. Int J Clin Oncol 2007, 12:284-8.
25. Braithe F, Rorud C, Esmail B, Kuzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005, 106:2992-4.
26. Haroche J, Amoura Z, Tran SG, Wechsler B, Cluzel P, Grenier PA, Pette JC. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006, 54:3306-8.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/11/77/prepub

doi:10.1186/1471-230X-11-77
Cite this article as: Pan et al.: Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterology 2011 11:77.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit